Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-na ïve and experienced HIV-1-infected Thai adults

Since it is currently not possible to completely eradicate HIV, the long-term use of combination antiretroviral therapy (cART) is necessary for life-long viral suppression and to prevent HIV disease progression. Therefore, a potent, non-toxic, and easy to take first-line antiretroviral therapy (ART) regimen is particularly important. Although most international treatment guidelines for HIV infection recommend the use of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or tenofovir alafenamide (TAF)/FTC plus an integrase inhibitor, recent World Health Organization (WHO) guidelines from 2016 continue to recommend TDF/FTC or TDF+lamivudine (3TC) + efavirenz (EFV) once daily as the preferred first-line regimen for resource-limited settings (WHO, 2017; European AIDS Clinical Society (EACS), 2017; Department of Health and Human Services (DHHS), 2017; Gunthard et al., 2016).

Source: International Journal of Infectious Diseases - June 13, 2017 Category: Infectious Diseases Authors: Anchalee Avihingsanon, Wirach Maek-a-nantawat, Sivaporn Gatechompol, Vorapot Sapsirisavat, Wanida Thiansanguankul, Jiratchaya Sophonphan, Narujakorn Thammajaruk, Sasiwimol Ubolyam, David M. Burger, Kiat Ruxrungtham Source Type: research